Clinical Trial Update: A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is testing an improved dose of UM171 to enhance the effectiveness and safety of cord blood transplantation; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy Requiring An Allogeneic Hematopoietic Stem Cell Transplant Without Donor
• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• UM171

Snippet

Sponsor: Ciusss de L'Est de l'Île de Montréal | Conditions: Acute Leukemia, High Risk, Myelodysplastic Syndromes, High Risk | Phase 1, Phase 2 | Status: RECRUITING